Friday, September 3, 2010
Thursday, September 2, 2010
Drug Discovery
Press Release
Innovative Symposium on Open-Source Drug Discovery Part of the 240th
National Meeting of the American Chemical Society
The ACS Division of Business Development and Management (BMGT) is
sponsoring a full day symposium on Open-Source Drug Discovery as part
of the 240th National Meeting of the American Chemical Society.
Speakers include pioneers of the open-source drug discovery movement
who will discuss their first-hand experiences in creating the tools
and platforms that enable the online collaboration of thousands of
scientists working to economically discover and develop much needed
drugs for the treatment of rare and neglected diseases.
Organized by Richard Harper of Indiana University-Purdue University
Indianapolis (IUPUI) and Bernard Munos of Eli Lilly, co-sponsored by
the ACS Division of Medicinal Chemistry and financially sponsored by
Eli Lilly and Company, the OSDD symposium provides an opportunity for
attendees to learn about the present and future of open-source
innovation and hear international practitioners from academia and
industry describe their approaches to setting up and operating open-
source drug R&D programs.
Scheduled for Monday, August 23, 2010 in Room 254A/B of the Boston
Convention & Exhibition Center, the morning session begins at 8:30
with opening remarks by Harper and Munos followed by presentations
from Dr. Samir Brahmachari of India’s Council for Scientific and
Industrial Research (CSIR)i, Dr. Christopher Austin from the NIH
Chemical Genomics Center and Dr. Solomon Nwaka of the World Health
Organization. After a short intermission, the session will continue
with talks by Dr. F. Javier Gamo of GlaxoSmithKline and Dr. Alpheus
Bingham from InnoCentive, and end with a panel discussion.
Harper and Munos will also open the afternoon session beginning at
1:30. Speakers will include Munos, Dr. Zakir Thomas
begin_of_the_skype_
the Open Source Drug Discovery program with CSIR, Dr. Marta Piñeiro-
Núñez of Eli Lilly and Company, Dr. William Scott from IUPUI and Dr.
Sean Ekins of Collaborative Drug Discovery. A final panel discussion
will end the symposium.
Some of the topics to be covered by these leading experts in open-
source drug discovery technology include activities at the NIH to
develop innovative and collaborative later stage drug development
programs, efforts by the WHO to foster novel approaches for research
in neglected diseases, the sharing by GSK of data on over 13,500
potential anti-malarial compounds, India’s OSDD program activities
involving 3000 people in 74 countries, Lilly’s phenotypic drug
discovery initiative (PD2), distributed drug discovery and
collaborative drug discovery and the various ways in which OSDD can
make it possible for global partnerships across academia, government
and industry to reduce the cost of drug development and make novel
treatments available for the very poor.
Directly following the symposium, there will be a reception and book
signing with Roger F. Jones, author of The Future of the Chemical
Industry, an ACS Symposium Series publication and his fourth and
latest book on industrial, technical, economic and managerial issues
in the chemical industry.
“We are very excited to be sponsors of this unique event at the
National ACS meeting,” states Dr Alan D. Palkowitz, Ph.D., Vice
President, Discovery Chemistry Research & Technologies, Eli Lilly and
Company. “The current pharmaceutical R&D model is being redesigned in
part by this new approach, which is also channeling drug research into
neglected and rare diseases. The speaker line-up represents people in
organizations involved at the forefront of this movement. This
symposium provides a forum for discussion of these early initiatives
and we hope the audience will be inspired to help build on this
foundation.”
--
You received this message because you are subscribed to the Google Groups "Open Source Drug Discovery" group.
To post to this group, send email to osdd-public@googlegroups.com.
To unsubscribe from this group, send email to osdd-public+unsubscribe@
For more options, visit this group at http://groups.google.com/
Innovative Symposium on Open-Source Drug Discovery Part of the 240th
National Meeting of the American Chemical Society
The ACS Division of Business Development and Management (BMGT) is
sponsoring a full day symposium on Open-Source Drug Discovery as part
of the 240th National Meeting of the American Chemical Society.
Speakers include pioneers of the open-source drug discovery movement
who will discuss their first-hand experiences in creating the tools
and platforms that enable the online collaboration of thousands of
scientists working to economically discover and develop much needed
drugs for the treatment of rare and neglected diseases.
Organized by Richard Harper of Indiana University-Purdue University
Indianapolis (IUPUI) and Bernard Munos of Eli Lilly, co-sponsored by
the ACS Division of Medicinal Chemistry and financially sponsored by
Eli Lilly and Company, the OSDD symposium provides an opportunity for
attendees to learn about the present and future of open-source
innovation and hear international practitioners from academia and
industry describe their approaches to setting up and operating open-
source drug R&D programs.
Scheduled for Monday, August 23, 2010 in Room 254A/B of the Boston
Convention & Exhibition Center, the morning session begins at 8:30
with opening remarks by Harper and Munos followed by presentations
from Dr. Samir Brahmachari of India’s Council for Scientific and
Industrial Research (CSIR)i, Dr. Christopher Austin from the NIH
Chemical Genomics Center and Dr. Solomon Nwaka of the World Health
Organization. After a short intermission, the session will continue
with talks by Dr. F. Javier Gamo of GlaxoSmithKline and Dr. Alpheus
Bingham from InnoCentive, and end with a panel discussion.
Harper and Munos will also open the afternoon session beginning at
1:30. Speakers will include Munos, Dr. Zakir Thomas
begin_of_the_skype_
the Open Source Drug Discovery program with CSIR, Dr. Marta Piñeiro-
Núñez of Eli Lilly and Company, Dr. William Scott from IUPUI and Dr.
Sean Ekins of Collaborative Drug Discovery. A final panel discussion
will end the symposium.
Some of the topics to be covered by these leading experts in open-
source drug discovery technology include activities at the NIH to
develop innovative and collaborative later stage drug development
programs, efforts by the WHO to foster novel approaches for research
in neglected diseases, the sharing by GSK of data on over 13,500
potential anti-malarial compounds, India’s OSDD program activities
involving 3000 people in 74 countries, Lilly’s phenotypic drug
discovery initiative (PD2), distributed drug discovery and
collaborative drug discovery and the various ways in which OSDD can
make it possible for global partnerships across academia, government
and industry to reduce the cost of drug development and make novel
treatments available for the very poor.
Directly following the symposium, there will be a reception and book
signing with Roger F. Jones, author of The Future of the Chemical
Industry, an ACS Symposium Series publication and his fourth and
latest book on industrial, technical, economic and managerial issues
in the chemical industry.
“We are very excited to be sponsors of this unique event at the
National ACS meeting,” states Dr Alan D. Palkowitz, Ph.D., Vice
President, Discovery Chemistry Research & Technologies, Eli Lilly and
Company. “The current pharmaceutical R&D model is being redesigned in
part by this new approach, which is also channeling drug research into
neglected and rare diseases. The speaker line-up represents people in
organizations involved at the forefront of this movement. This
symposium provides a forum for discussion of these early initiatives
and we hope the audience will be inspired to help build on this
foundation.”
--
You received this message because you are subscribed to the Google Groups "Open Source Drug Discovery" group.
To post to this group, send email to osdd-public@googlegroups.com.
To unsubscribe from this group, send email to osdd-public+unsubscribe@
For more options, visit this group at http://groups.google.com/
Subscribe to:
Posts (Atom)
